DCAL2023-10-012023-12-31 DCAL2023-10-012023-12-31 DCAL2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member DCAL2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member DCAL2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member DCAL2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member DCAL2023-12-31 DCAL2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DCAL2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member DCAL2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss03Member DCAL2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DCAL2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member DCAL2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss03Member DCAL2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DCAL2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member DCAL2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member DCAL2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 540701 DCAL NA Dishman Carbogen Amcis Limited Equity 2023-04-01 2024-03-31 2024-02-14 2024-02-06 INR Crores Third quarter 15:00:00 18:45:00 2024-02-14 2024-02-14 Not applicable Single segment Contract Research and Manufacturing Services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, disinfectants etc 2023-10-01 2023-12-31 Unaudited Consolidated 6510900000.00 60500000.00 6571400000.00 2025300000.00 0.00 -844100000.00 3092000000.00 330800000.00 803700000.00 1826600000.00 7234300000.00 -662900000.00 0.00 -662900000.00 8000000.00 -74600000.00 -66600000.00 0.00 -596300000.00 0.00 0.00 0.00 0.00 -596300000.00 2747700000.00 2151400000.00 -596300000.00 2151400000.00 0.00 313600000.00 2 -3.80 -3.80 0.00 0.00 -3.80 -3.80 Notes: 1. The SaaS cost related to current IT project (D365), for the quarter ended 31st December, 2023, 30th September, 2023, 31st December, 2022, for the nine months ended 31st December, 2023, nine months ended 31st December, 2022 and for the year ended 31st March, 2023 amounts to INR 1.46 Crores, INR 2.25 Crore, INR 1.00 Crores, INR 8.45 Crores, INR 6.81 Crores and INR 10.58 Crores respectively. These costs were directly expensed in the books of subsidiary companies and not capitalized due to the recently published IFRIC agenda decision (Configuration or Customisation Costs in a Cloud Computing Arrangement (IAS 38 Intangible Assets)-Agenda Paper 2) which clarified the recognition criteria for such arrangements. 2. Other expenses for the quarter and nine months ended 31st December, 2023 includes forex loss of INR 76.37 crores and 76.74 crores respectively, majorly due to abnormal movement between USD/CHF resulting in mark to market notional loss on foreign currency bank account revaluation in one of the subsidiaries. The core Earnings before Interest, Tax and Depreciation and Amortisation and SaaS cost (EBITDA) for the quarter and nine months ended 31st December, 2023 excluding the same is INR 118.94 crores and INR 309.01 crores, respectively. Note: for full notes to FR, refer Quick Result Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 19610600000.00 210500000.00 19821100000.00 4424900000.00 0.00 -267100000.00 8873900000.00 890200000.00 2258600000.00 4340700000.00 20521200000.00 -700100000.00 -30500000.00 -730600000.00 278700000.00 -174000000.00 104700000.00 0.00 -835300000.00 0.00 0.00 0.00 0.00 -835300000.00 2598500000.00 1763200000.00 -835300000.00 1763200000.00 0.00 313600000.00 2 -5.33 -5.33 0.00 0.00 -5.33 -5.33 Other Expenditure (Refer Note No. 10) 1812000000.00 SaaS IT Project Cost (Refer Note No. 9) 14600000.00 Other Expenditure (Refer Note No. 10) 4256200000.00 SaaS IT Project Cost (Refer Note No. 9) 84500000.00 Remeasurement gain/(losses) on defined benefit plans -300000.00 Income Tax effect -1000000.00 Changes in fair value of FVTOCI equity instruments 300000.00 Remeasurement gain/(losses) on defined benefit plans -207800000.00 Income Tax effect 25100000.00 Changes in fair value of FVTOCI equity instruments 1700000.00 -1000000.00 -181000000.00 100000.00 600000.00 Movement in foreign currency translation reservet 3084400000.00 Foreign exchange fluctuations in respect of cash flow hedge -516200000.00 Movement in foreign currency translation reservet 3033000000.00 Foreign exchange fluctuations in respect of cash flow hedge -388700000.00 2568200000.00 2644300000.00 -180600000.00 -135800000.00